Video
Dr. Dason on selecting neoadjuvant or adjuvant therapy for patients with UTUC
Author(s):
“We definitely don't have a clear standard,” says Shawn Dason, MD, FRCSC.
Video Player is loading.
In this video, Shawn Dason, MD, FRCSC, discusses the factors that urologists should consider when counseling patients with upper tract urothelial carcinoma about neoadjuvant and adjuvant treatment options. These insights stem from a study that was presented at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference. Dason is a urologic oncologist and an assistant professor of urology at The Ohio State University in Columbus.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera’s SNM device
Ashley Winter, MD, calls for label update on low-dose vaginal estrogen
Joseph Song, MD, on the emergence of new suction-based devices for stone disease
How eating disorders affect bladder and pelvic floor health
Daniel D. Joyce, MD, MS, discusses the economics of trimodal therapy in MIBC
Sarah Razavi, MD, outlines strategies for mitigate surgeon discomfort during URS
Can ctDNA detect molecular residual disease in NMIBC?
Expert discusses setting realistic expectations for Rezum for BPH
Nicolette G. Payne, MD, discusses risk factors for burnout among pediatric urologists
Sacral neuromodulation device empowers patients with greater UUI control
Related Content
